Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuanju compound capsule versus terazosin for chronic non-bacterial prostatitis
ACTRN12613000885796Phase 3Withdrawn
- Sponsor
- Zhoutie Pharmaceutical
- Start
- Feb 2014
- Countries
- 2
01
Overview
Phase 3, open-label trial of compound xuanju in chronic prostatitis (CP) and Prostatodynia (CP/CPPS) (2 arms), sponsored by Zhoutie Pharmaceutical. Primary endpoint: NIH Chronic Prostatitis Symptom Index score. Planned start Feb 2014; status: withdrawn.
02
Drugs
compound xuanju
03
Conditions
chronic prostatitis (CP)Prostatodynia (CP/CPPS)
Beyond the preview
Go deeper on ACTRN12613000885796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000885796.